The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Development And Evaluation Of Novel Antibacterial Coatings For The Prevention Of Infection On Biomedical Devices
Funder
National Health and Medical Research Council
Funding Amount
$284,402.00
Summary
This project aims to develop infection-resistant coatings that can be applied to a wide range of biomedical devices used in human health care. Novel antibacterial compounds from Australian plants (genus Eremophila) will be coated as thin layers onto model materials used for biomedical device fabrication, then onto real-life biomedical products and evaluated for ability to deter colonization by biofilm-forming human pathogenic bacteria.
The Development Of Novel, Biofilm-resistant Biomaterials
Funder
National Health and Medical Research Council
Funding Amount
$147,360.00
Summary
Almost all patients who are catheterised long term develop a bacterial infection. Most often, the infection is the result of colonisation of the catheter surface by bacteria. Bacterial colonisation of the surface of biomedical devices represents a significant health threat as such bacterial biofilms are extremely resistant to traditional antibiotic regimens. This project aims to develop novel materials that prevent bacterial colonisation on catheters and other biomedical related devices. Our tec ....Almost all patients who are catheterised long term develop a bacterial infection. Most often, the infection is the result of colonisation of the catheter surface by bacteria. Bacterial colonisation of the surface of biomedical devices represents a significant health threat as such bacterial biofilms are extremely resistant to traditional antibiotic regimens. This project aims to develop novel materials that prevent bacterial colonisation on catheters and other biomedical related devices. Our technology is based on compounds identified from a marine alga that prevent bacterial colonisation of its surface. Similarly, we have shown that these compounds, when coated onto test surfaces, prevent bacterial colonisation of a range of materials.Read moreRead less
Recombinant Bacteria Expressing Oligosaccharide Receptor Mimics For Prevention Of Enteric Infections
Funder
National Health and Medical Research Council
Funding Amount
$451,056.00
Summary
Gastrointestinal infectious diseases kill more than 3 million people each year. The principal microbial pathogens responsible for these infections are known to exploit oligosaccharides on the surface of host cells as receptors for ahesins or toxins. We have developed (and patented) a novel anti-infective strategy, based on mimicry of oligosaccharide receptors for toxins and adhesins produced by enteric pathogens on the surface of harmless carrier bacteria. Oral administration of such recombinant ....Gastrointestinal infectious diseases kill more than 3 million people each year. The principal microbial pathogens responsible for these infections are known to exploit oligosaccharides on the surface of host cells as receptors for ahesins or toxins. We have developed (and patented) a novel anti-infective strategy, based on mimicry of oligosaccharide receptors for toxins and adhesins produced by enteric pathogens on the surface of harmless carrier bacteria. Oral administration of such recombinant probiotics has the potential to prevent enteric infections by binding and neutralizing toxins in the gut lumen and by blocking adherence of the pathogen to intestinal epithelial cells. As a prototypic example, we have developed a bacterium capable of preventing the serious consequences of Shiga toxigenic Escherichia coli (STEC) infections; this agent binds Shiga toxin with very high efficiency and is 100% protective in animal models. The strategy has very broad applications, however, and receptors for virtually any pathogen can be mimicked by expression of appropriate glycosyl transferases in a suitable harmless host bacterium. This proposal involves extension of our existing work to develop therapeutic agents for other important life threatening diarrhoeal diseases including cholera, travellers' diarrhoea, dysentery, antibiotic-associated colitis, rotavirus, etc.Read moreRead less
Commercialisation Of A Glycoprofiling Diagnostic Kit And Novel Therapies For Biofilm Related Respiratory Disorders
Funder
National Health and Medical Research Council
Funding Amount
$203,050.00
Summary
Our preliminary studies have shown that a group of patients who suffer from chronic inflammatory disease and have bacterial biofilm identified on their mucosa have worse outcomes even after surgery. We have shown that they lack certain small protein and sugar molecules on their respiratory lining. We aim to use this technology as a diagnostic tool to aid the doctor in prescribing the appropriate treatment for these patients to prevent bacteria regrowing in their respiratory tract.
Development Of Small Molecule IRAP Inhibitors For Treating Memory Deficits
Funder
National Health and Medical Research Council
Funding Amount
$369,898.00
Summary
We have identified a series of small molecule compounds based on their ability to inhibit the catalytic activity of a protein, IRAP using a computer model of IRAP to screen chemical libraries. This research proposal aims to investigate the properties of these compounds and their ability to treat Alzheimer's dementia. At the conclusion of this project, we will have 2 families of lead compounds suitable for development into a new class of therapeutic agents for treating Alzheimer's disease.
Development Of Small Molecule Inhibitors Of IRAP - Potential Use For The Treatment Of Memory Disorders
Funder
National Health and Medical Research Council
Funding Amount
$195,450.00
Summary
This research project provides proof of concept that IRAP is a suitable target for use in the development of a new class of clinically valuable cognitive-enhancing agents. We have recently Identified a family of small molecule compounds that inhibited the catalytic activity of the enzyme using a molecule model of IRAP to screen virtual libraries. This research proposal aims to validate that this family of compounds have memory-enhancing properties by acting specifically on IRAP. At the conclusio ....This research project provides proof of concept that IRAP is a suitable target for use in the development of a new class of clinically valuable cognitive-enhancing agents. We have recently Identified a family of small molecule compounds that inhibited the catalytic activity of the enzyme using a molecule model of IRAP to screen virtual libraries. This research proposal aims to validate that this family of compounds have memory-enhancing properties by acting specifically on IRAP. At the conclusion of this project, we will have elucidated important information on the specificity of the memory effects and the structure activity relationship of this family of compounds. We will have identified and characterised a lead compound for development into a new class of cognitive enhancers.Read moreRead less